Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLAY: Aliskiren vs Losartan for LVH Regression
NCT00219141Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in hypertension (HTN) and left ventricular hypertrophy (LVH) (3 arms), sponsored by Novartis. Primary endpoint: Change in Left Ventricular Mass Index at 36 weeks. Started Oct 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT00219141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219141.